Several other studies are being conducted on sobetirome, a thyroid hormone receptor agonist, and pioglitazone, a PPARγ agonist. Antioxidant therapy has also shown some persuasive results demanding a larger study whereas treatment with Gene therapy including Ex vivo lentiviral gene correction and in vivo adeno-associated virus 9 (AAV9) based gene therapy is being pursued.
Lovastatin is an anti cholesterol drug that normalized plasma VLCFA in one study but showed no normalization to placebo in randomized double‐blind crossover trial. 
Several other studies are being conducted on sobetirome, a thyroid hormone receptor agonist,  and pioglitazone, a PPARγ agonist.
High-dose antioxidants have been seen in a limited open-label study with adolescents with AMN. Progress has been seen in a 6-minute walk test, which demands a larger study. 
N-Acetyl cysteine (NAC) adjunct therapy for individuals undergoing allogeneic HSCT has been shown to improve survival in patients with more advance neurological deficit.
Ex vivo lentiviral gene Correction and in vivo adeno-associated virus 9 (AAV9)-based gene therapy is being pursued. The latter has shown to correct the metabolism of VLCFA in mice, although the former has also demonstrated positive effects in a study involving 17 ALD boys with early-stage brain disease who underwent Lenti-D ABCD1 gene therapy and confirmed that 15 of the patients survived the therapy. There was no treatment related death or graft versus host disease seen in them.
Adrenoleukodystrophy future or investigational therapies
Multiple sclerosis alternative therapies
Adrenoleukodystrophy secondary prevention
Multiple sclerosis tertiary prevention
Adrenoleukodystrophy medical therapy
Multiple sclerosis primary prevention
Mixed connective tissue disease medical therapy
Polymyositis and dermatomyositis secondary prevention